ロード中...
Inhibition of Hsp90 Augments Docetaxel Therapy in Castrate Resistant Prostate Cancer
First line treatment of patients with castrate resistant prostate cancer (CRPC) primarily involves administration of docetaxel chemotherapy. Unfortunately, resistance to docetaxel therapy is an ultimate occurrence. Alterations in androgen receptor (AR) expression and signaling are associated mechani...
保存先:
| 主要な著者: | , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Public Library of Science
2014
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4114978/ https://ncbi.nlm.nih.gov/pubmed/25072314 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0103680 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|